Business

US Judge Approves $11 Billion Bayer Roundup Settlement

A St. Louis circuit judge has authorized an $11 billion settlement to resolve thousands of cancer-related lawsuits linked to the herbicide Roundup.

A St. Louis circuit judge has granted approval for a settlement valued at approximately $11 billion (US$7.25 billion) to resolve thousands of legal claims against Bayer, the company behind the widely used herbicide Roundup. The court-approved agreement addresses claims from users who are currently ill as well as those who may be diagnosed with non-Hodgkin lymphoma in the future, providing a structured mechanism to mitigate the company’s significant and mounting litigation costs.

In his written judgment, St. Louis Circuit Judge Timothy Boyer described the average individual payouts—which range between $10,000 and $165,000 depending on factors such as how the product was used, the user’s age at diagnosis, and the severity of their illness—as “fair and adequate.” The judge also noted that the total dollar amount of the settlement is “among the largest in the history of mass tort personal-injury class action settlements.” Furthermore, Judge Boyer indicated that there was a tangible risk that Bayer might have sought bankruptcy protection had the court rejected the agreement.

Bayer, a Germany-based chemical manufacturer, continues to deny that Roundup causes cancer. Nevertheless, the company views the settlement as a vital step in managing its exposure to long-term litigation. About 200,000 Roundup-related claims have been filed against the company, many originating from individuals who used the product on residential lawns and gardens. In response to these legal and commercial challenges, Bayer has already altered the formula for versions of Roundup sold in residential markets, removing glyphosate, the active ingredient at the center of the cancer allegations. Bayer CEO Bill Anderson stated that the court-approved resolution represents “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.”

For decades, Roundup has been a staple in agricultural production. Since its debut by Monsanto in 1974, it has become one of the world’s most widely used herbicides. The product is frequently used in tandem with genetically modified seeds engineered to resist the herbicide, allowing farmers to increase yields while conserving soil through reduced tilling. Despite its agricultural utility, the product has faced intense scrutiny regarding its health impacts.

The litigation environment surrounding the product has been complex. In June, the US Supreme Court ruled that Bayer cannot be held liable in state courts on claims that it failed to warn consumers about cancer, citing federal regulations that do not require such a cancer warning label and prohibit states from imposing additional requirements. This ruling established a significant legal obstacle for plaintiffs. While some legal representatives for patients have argued that the settlement payouts are insufficient, others have acknowledged that the deal offers a more favorable outcome than the potential for no recovery at all following the Supreme Court’s intervention.

While the US litigation moves toward resolution, legal actions in other jurisdictions have reached different outcomes. In Australia, all class actions alleging that Roundup caused cancer have concluded without compensation. The Federal Court of Australia dismissed the “McNickle” case in July 2024, determining that there was insufficient evidence to establish that glyphosate causes non-Hodgkin lymphoma. A subsequent legal challenge, the “Fenton” class action, was discontinued in January 2025, with no further appeals pursued, bringing the Australian litigation to a close.

The approved US settlement includes $600 million designated for legal fees. Although the decision remains subject to potential appeal, the ruling represents a significant development in the decade-long controversy surrounding the herbicide.

Mia Reynolds

Mia Reynolds covers companies, entrepreneurship, leadership, and changing industries. She turns complex business developments into accessible stories, helping readers follow corporate decisions, market shifts, and trends influencing the global business landscape.
Back to top button